Researchers at Stanford have developed an IL-7–conjugated lipid nanoparticle (LNP) platform designed to substantially improve mRNA delivery to T cells for direct in vivo T-cell engineering.
Stanford researchers have developed a next-generation programmable transcriptional activation platform, TIGRa, that addresses key limitations of CRISPRa technologies, including large size, limited multiplexing capacity, and delivery constraints.
Researchers at Stanford have designed, in silico, a series of new human IL-2 mutants that have biased actions on different immune cell subsets, and confer increased signaling potency compared to natural IL-2.
Stanford scientists have developed a thin, wearable electrode array patch capable of non-invasively recording high-resolution electrical signals through the skin of the body's internal organs, offering a new window into physiological processes that have historically been diffi
Stanford researchers have developed Microbe-Independent Deep Assembly and Screening (MIDAS-M), a novel platform that dramatically accelerates the cloning of protein variants and its analysis in mammalian cells.
Researchers in Prof. Mark Schnitzer's laboratory have developed a robotic optical microscopy system which enables users to simultaneously view and record separate areas of a single three-dimensional sample.
Stanford researchers have developed a personalized arrhythmia risk prediction tool for dilated cardiomyopathy (DCM) patients using patient-derived induced pluripotent stem cells (iPSCs) to replicate heart biology and accurately predict arrhythmia risk, enabling timely interven
Imaging methods that can visualize biological samples with high and temporal resolution are critical for modern biomedical research and clinical practice.
Stanford scientists have discovered novel high molecular weight isoforms of thymic stromal lymphopoietin (TSLP), measured using nanoimmunoassay (NIA), that can serve as a blood-based biomarker for the diagnosis and prognostication of acute graft versus host disease (aGVHD).
Stanford researchers have developed a targeted antisense oligonucleotide (ASO) platform to restore physiological regulation of DYRK1A, a key driver of neurodevelopmental and neurodegenerative pathology in Down syndrome (Trisomy 21) and other tauopathies.
Researchers from Stanford have developed a novel topical pharmaceutical composition comprising of a chemical inhibitor encapsulated in nanomicelles for the treatment of vision loss associated with acute optic neuropathies.
Researchers at Stanford, in collaboration with UCSF, have developed a two-part approach to preventing preterm birth (PTB), the leading cause of infant mortality worldwide. Current treatments, like low-dose aspirin and progesterone, are limited and often ineffective.
Scientists at Stanford have developed a novel imaging approach that enables high-resolution, label-free visualization of subcellular structures in living cells.